Amylyx ALS drug shows no serious adverse events in Phase 1 trial

June 23, 2026 7:00 AM

Amylyx Pharmaceuticals (NASDAQ: AMLX) presented early data from the Phase 1 LUMINA trial of its investigational drug AMX0114 for amyotrophic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found